- Home
- TNYA
as 08-04-2025 9:51am EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 111.1M | IPO Year: | 2021 |
| Target Price: | $8.60 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $4.01 | Next Earning Date: | 08-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tingley Whittemore | TNYA | Chief Medical Officer | May 16 '25 | Sell | $0.44 | 2,937 | $1,300.21 | 171,856 | |
| Ali Faraz | TNYA | Chief Executive Officer | May 16 '25 | Sell | $0.44 | 3,189 | $1,411.77 | 317,325 | |
| Higa Tomohiro | TNYA | SVP, Finance | May 16 '25 | Sell | $0.44 | 1,390 | $615.35 | 98,300 |
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
3 months ago
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Simply Wall St.
3 months ago
We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
GlobeNewswire
3 months ago
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
Clinical Trials Arena
4 months ago
Tenaya highlights HCM gene therapy interim data at ACC 2025
GlobeNewswire
4 months ago
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Insider Monkey
4 months ago
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?
Compare TNYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.